Amishi Y. Shah

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 21 papers. Top paper: “Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study”.

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00241-2

N/A

5.2DataRank · unranked

186 citations

Amishi Y. Shah, Drew Rasco, Arpit Rao, Matthew H. Taylor, Christopher Di Simone +23 more

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies

Cancer(2020)10.1002/cncr.33328

N/A

3.1DataRank · unranked

113 citations

Matthew T. Campbell, Wanling Xie, Subrina Farah, Mehmet Asım Bilen, Andrew Schmidt +11 more

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

ESMO Open(2024)10.1016/j.esmoop.2024.102994

N/A

1.9DataRank · unranked

94 citations

Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah +15 more

Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00095-0

N/A

0.807DataRank · unranked

27 citations

Vania Balderrama-Brondani, Camilo Jiménez, Gina Tamsen, Leonardo P. Marcal, Jeena Varghese +7 more

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Annals of Oncology(2025)10.1016/j.annonc.2025.09.006

N/A

0.719DataRank · unranked

18 citations

Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B. Apolo, María T. Bourlon +16 more

Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma

The Journal of Urology(2024)10.1097/ju.0000000000003928

N/A

0.411DataRank · unranked

8 citations

Mehrad Adibi, Amishi Y. Shah, Omar Alhalabi, Paul G. Corn, Charles C. Guo +8 more

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial

Nature Communications(2025)10.1038/s41467-024-55642-8

N/A

0.406DataRank · unranked

12 citations

Herbert Yu, Ying Yuan, Jianfeng Chen, Xinmiao Yan, Menuka Karki +22 more

High-intensity exercise is a risk factor for renal medullary carcinoma in individuals with sickle cell trait

medRxiv(2021)10.1101/2021.02.23.21252313

N/A

0DataRank · unranked

0 citations

Melinda Soeung, Luigi Perelli, Eleonora Dondossola, Devaki Shilpa Surasi, Durga Nand Tripathi +20 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3

N/A

0DataRank · unranked

117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience

The Journal of Clinical Endocrinology & Metabolism(2022)10.1210/clinem/dgac046

N/A

0DataRank · unranked

32 citations

Jeena Varghese, Stephen K. Gruschkus, Camilo Jiménez, Steven G. Waguespack, Sara Bedrose +15 more

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Nature Communications(2023)10.1038/s41467-023-38342-7

N/A

0DataRank · unranked

49 citations

Pavlos Msaouel, Cara Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita +17 more

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

npj Precision Oncology(2023)10.1038/s41698-023-00369-w

N/A

0DataRank · unranked

7 citations

Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang +16 more

Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis

The Oncologist(2024)10.1093/oncolo/oyae099

N/A

0DataRank · unranked

2 citations

Vania Balderrama-Brondani, Kelsey Ruth Herrera, Brenda Chahla, Feyza Yaylaci, Roland L. Bassett +8 more

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2023.7119

N/A

0DataRank · unranked

2 citations

Nicolas L. Palaskas, Bilal A. Siddiqui, Jennifer L. McQuade, Jamie S. Lin, Sumit K. Subudhi +8 more

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1917

N/A

0DataRank · unranked

2 citations

John F. Ward, Wayne L. Hofstetter, David C. Rice, José A. Karam, Louis L. Pisters +24 more

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0751

N/A

0DataRank · unranked

11 citations

Andrew W. Hahn, Pavlos Msaouel, Alexander Andreev-Drakhlin, Funda Meric‐Bernstam, Aung Naing +17 more

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-003277

N/A

0DataRank · unranked

118 citations

David M. Faleck, Anusha Shirwaikar Thomas, Jessica Harris, Deepika Satish, Xuemei Wang +13 more

Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies

The Oncologist(2021)10.1002/onco.13770

N/A

0DataRank · unranked

37 citations

Tharakeswara Bathala, Andrew W. Hahn, Lianchun Xiao, Munevver Duran, Jeremy A. Ross +6 more

Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.08.007

N/A

0DataRank · unranked

36 citations

Andrew James Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Pheroze Tamboli +7 more

Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation

British Journal of Urology(2021)10.1111/bju.15541

N/A

0DataRank · unranked

33 citations

Aradhana M. Venkatesan, Pavlos Msaouel, Amol J. Ghia, Jing Li, D.N. Yeboa +13 more

Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.07.004

N/A

0DataRank · unranked

2 citations

Andrew W. Hahn, Pavlos Msaouel, Funda Meric‐Bernstam, Nathaniel R. Wilson, Aung Naing +18 more